Prevention of postpartum methamphetamine use with micronized progesterone trial (PROMPT): A pilot randomized controlled trial.

In 30 seconds

The PROMPT trial evaluated the feasibility and safety of micronized progesterone in preventing postpartum methamphetamine use among individuals with methamphetamine use disorder. This pilot randomized controlled trial enrolled 34 participants, finding that while retention was high at 88%, there was no significant difference in return to methamphetamine use between the progesterone and placebo groups.

Key findings

• Of 253 screened individuals, 34 were enrolled, achieving 91.8% of planned enrollment.
• Retention at 12 weeks was 88%, indicating strong participant adherence.
• Adverse event frequency was similar between groups at 78% for progesterone and 81% for placebo.
• Craving trajectories differed based on medication for opioid use disorder.

Why it matters

Understanding effective strategies to prevent postpartum methamphetamine use is crucial for improving maternal and infant health outcomes. This study provides preliminary insights into the potential role of progesterone in this context.